23:01 , Mar 21, 2019 |  BC Extra  |  Financial News

Qiming backs Abbisko in $42M series B

Abbisko raised a $42 million series B round led by new investor Qiming Venture Partners to advance its oncology compounds into the clinic and further expand its discovery pipeline. Abbisko Therapeutics Co. Ltd. (Shanghai, China)...
21:28 , Feb 9, 2018 |  BioCentury  |  Emerging Company Profile

Fast boat to China

Abbisko Therapeutics aims to be first-to-market for common cancer indications in China with small molecules against clinically validated targets that are more potent than competing agents in development outside the country. Abbisko is focusing first...
20:43 , Feb 10, 2017 |  BC Week In Review  |  Financial News

Abbisko completes venture financing

Cancer company Abbisko Therapeutics (Shanghai, China) raised $28 million in a series A round from Lilly Asia Ventures, Sinopharm Capital, Jianxin Capital and TF Capital on Feb. 5. Abbisko Therapeutics , Shanghai, China ...
23:55 , Feb 6, 2017 |  BC Extra  |  Financial News

Abbisko raises $28M in series A

Abbisko Therapeutics (Shanghai, China) said it raised $28 million in a series A financing from Lilly Asia Ventures, Sinopharm Capital, Jianxin Capital and TF Capital. Abbisko's website lists three preclinical compounds, including lead candidate ABSK001...